Antiandrogens: all 479 studies that test it
Page 5 of 5. Open to participants first (92), then studies with results posted, then the rest; newest registration first within each.
- A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of GenesCompletedNCT02069730Not applicable
- Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the ProstateCompletedNCT02064036Phase 1
- A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male ParticipantsCompletedNCT02031666Phase 1
- Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by AntioxidantsStatus unknownNCT02027337Phase 4
- Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate CancerActive, not recruitingNCT02023463Phase 1
- MEdical Versus SUrgical Treatments of Rectal EndometriosisCompletedNCT01973816Phase 3
- Androgen Deprivation Therapy in Advanced Salivary Gland CancerCompletedNCT01969578Phase 2
- Drug-drug Interaction Study With MDV3100 (ASP9785) and Gemfibrozil and ItraconazoleCompletedNCT01913379Phase 1
- A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male SubjectsCompletedNCT01911741Phase 1
- Drug-drug Interaction Study With MDV3100 and a Cocktail of SubstratesCompletedNCT01911728Phase 1
- A Study to Explore the Routes of Elimination of MDV3100CompletedNCT01911715Phase 1
- Relative Bioavailability Study of Enzalutamide in Prostate Cancer PatientsCompletedNCT01902251Phase 1
- Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control GroupCompletedNCT01901133Phase 1
- 14C-ARN-509 Microtracer Label AME and Absolute BA StudyCompletedNCT01822041Phase 1
- Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone AcetateCompletedNCT01792687Phase 1
- Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate CancerCompletedNCT01784757Phase 1
- the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary SyndromeStatus unknownNCT01752270Phase 4
- Degarelix Neo-Adjuvant Radical Prostatectomy TrialCompletedNCT01674270Phase 2
- A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate CancerWithdrawnNCT01663415Phase 2
- Comparison of Body Weight Change During Contraception With Belara and YasminStatus unknownNCT01608698Phase 4
- Efficacy of Metformin and Diane-35 on PCOS Patients,a Randomized, Controlled, Prospective Clinical TrialCompletedNCT01573377Not applicable
- The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic CancerStatus unknownNCT01487902Phase 2
- Oral Mucosal Absorption Study of Bicalutamide New FormulationTerminatedNCT01416883Phase 1
- Bioequivalence of Bicalutamide New Formulation in JapanTerminatedNCT01416870Phase 1
- Oral Mucosal Absorption of ICI176,334-1CompletedNCT01415791Phase 1
- Bioequivalence of ICI176,334-1 in Japanese Healthy Male SubjectsCompletedNCT01415778Phase 1
- Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid TumorsCompletedNCT01362374Phase 1
- A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer PatientsCompletedNCT01284920Phase 1/2
- Progestagen Type in Postmenopausal Hormone Therapy and Blood Gene Expression ProfileStatus unknownNCT01123538Phase 4
- Ethinyl Estradiol and Cyproterone Acetate in Irregular MenstruationStatus unknownNCT01103518Phase 4
- Sex Steroids and the Serotonin TransporterCompletedNCT01065220Phase 4
- Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate CancerCompletedNCT01050842Early Phase 1
- Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex 50 mg Tablet in Healthy Subjects Under Fasting ConditionsCompletedNCT01039233Phase 1
- Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate AdenocarcinomaCompletedNCT01011751Phase 3
- Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fasting ConditionsCompletedNCT00973050Phase 1
- Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fed ConditionsCompletedNCT00972855Phase 1
- Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed ConditionsCompletedNCT00960310Phase 1
- Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting ConditionsCompletedNCT00959335Phase 1
- Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary SyndromeStatus unknownNCT00930228Phase 1
- Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for BrachytherapyCompletedNCT00866554Phase 2
- Radiation Therapy With or Without Goserelin and Cyproterone in Treating Patients With Prostate CancerCompletedNCT00849082Phase 3
- Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate CancerCompletedNCT00846976Phase 3
- Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,cCompletedNCT00817739Phase 2
- Radiation Therapy and Hormone Therapy in Treating Patients With Prostate CancerCompletedNCT00769548Phase 3
- Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation TherapyCompletedNCT00684905Phase 2
- (Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate CancerCompletedNCT00673205Phase 3
- Casodex vs Placebo in Non-Metastatic Early Prostate CancerCompletedNCT00672282Phase 3
- Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate CancerCompletedNCT00657904Phase 3
- Casodex - Nolvadex CombinationCompletedNCT00637871Phase 2
- Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEXCompletedNCT00590213Phase 4
- Bicalutamide Monotherapy Has Significant Quality of Life Benefits for Men With Advanced Prostate CancerCompletedNCT00551044Not applicable
- RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local SurgeryCompletedNCT00541047Phase 3
- Positive Surgical Margins Rate and EGFR Family Members Expression in Prostate Cancer Treated With BicalutamideCompletedNCT00421694Phase 2/3
- Survival Outcomes and Tumor Molecular Profile Following Bicalutamide Neoadjuvant TherapyCompletedNCT00418080Phase 2
- Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate CancerStatus unknownNCT00363285Phase 3
- Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate CancerCompletedNCT00349557Phase 2
- Casodex/Zoladex Biomarkers in Localised Prostate CancerCompletedNCT00293696Phase 4
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyActive, not recruitingNCT00268476Phase 2/3
- CMAB vs IMAB in Metastatic Prostate CancerWithdrawnNCT00255268Phase 4
- Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized TrialTerminatedNCT00243646Phase 3
- Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy AloneActive, not recruitingNCT00223145Phase 3
- Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate CancerCompletedNCT00116220Phase 3
- Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate CancerCompletedNCT00104741Phase 3
- Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical ProstatectomyCompletedNCT00086736Phase 2
- Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate CancerCompletedNCT00067015Phase 3
- Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate CancerCompletedNCT00031889Phase 2
- Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate CancerCompletedNCT00030654Phase 3
- Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate CancerCompletedNCT00023829Phase 3
- Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate CancerCompletedNCT00021450Phase 3
- Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate CancerCompletedNCT00020254Phase 2
- Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate CancerTerminatedNCT00014586Phase 3
- Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or PeritoneumCompletedNCT00012090Phase 2
- Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate CancerCompletedNCT00006359Phase 2
- Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the ProstateCompletedNCT00006214Phase 2
- Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate CancerCompletedNCT00005623Phase 3
- Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate CancerCompletedNCT00003653Phase 3
- Hormone Therapy in Treating Patients With Prostate CancerCompletedNCT00003323Phase 2
- Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate CancerCompletedNCT00002881Phase 3
- Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate CancerCompletedNCT00002855Phase 3